Last reviewed · How we verify
NCT06376032
EndeavorOTC® Research Study in College Students
NA trial testing EndeavorOTC® in Attention in 69 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | Akili Interactive Labs, Inc. |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 69 |
| Start date | 10 January 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- EndeavorOTC®
Conditions studied
- Attention — all drugs for Attention →
- Cognition — all drugs for Cognition →
- University Students — all drugs for University Students →
Sponsor
Akili Interactive Labs, Inc.
Who can join
18 and older, any sex, with Attention or Cognition. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate the impact of a digital therapeutic (EndeavorOTC®, also known as AKL-T01A) on clinical symptoms of executive and cognitive functioning in a real-world sample of university students. This study aims to answer whether EndeavorOTC represents a useful intervention for targeting broad cognitive and emotional health among university students.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06376032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Attention
Currently open trials in the same condition.
- NCT07266909 — Impact of Attentional Tunelling on a Population of French Practitioners · recruiting
- NCT07408180 — Exploratory Randomized, Controlled, Dose-response Study on the Impact of Nicotine From Five Variants of a Nicotine Table · NA · active not recruiting
- NCT06837246 — A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population · NA · recruiting
- NCT06587113 — An Investigation of Attentional and Inhibitory Processes During Active Visual Search in Humans · NA · recruiting
- NCT06248268 — Neuropsychological Patterns of Suicide Ideators and Suicide Attempters · recruiting
Other Akili Interactive Labs, Inc. trials
Trials by the same sponsor.
- NCT06109051 — EndeavorOTC™ Prospective Product Registry · active not recruiting
- NCT05991167 — EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx") · active not recruiting
- NCT05183919 — Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult) · NA · completed
- NCT04897074 — Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents) · NA · completed
- NCT03844269 — Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06376032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akili Interactive Labs, Inc.
- Last refreshed: 27 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06376032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing